Modulation of morphine-induced antinociception by ibogaine and noribogaine.
A A Bagal, L B Hough, J W Nalwalk, Stanley D Glick
Brain Research November 25, 1996 DOI: 10.1016/s0006-8993(96)00938-9 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Rats |
| Interventions | Ibogaine Noribogaine Morphine |
| Dose | 40 mg/kg ibogaine, 4 mg/kg morphine, 1-40 mg/kg ibogaine, 40 mg/kg noribogaine |
| Topics | Ibogaine |
| Citations | 23 |
| Key findings | Ibogaine pretreatment (19 h) reduces morphine antinociception, while co-administration of ibogaine or noribogaine enhances it. |
Abstract
The potential modulation of morphine antinociception by the putative anti-addictive agent ibogaine and its active metabolite (noribogaine) was investigated in rats with the radiant heat tail-flick test. Ibogaine pretreatment (40 mg/kg, i.p., 19 h) significantly decreased morphine (4 mg/kg, s.c.) antinociception, with no effects in the absence of morphine. However, co-administration of ibogaine (1-40 mg/kg, i.p.) and morphine (4 mg/kg, s.c.) exhibited a dose-dependent enhancement of morphine antinociception. Co-administration of noribogaine (40 mg/kg, i.p.) and morphine also resulted in an increase in morphine antinociception, while noribogaine pretreatment (19 h) had no effect on morphine antinociception. The results show that ibogaine acutely potentiates morphine antinociception and that noribogaine could be the active metabolite responsible for this effect. However, the inhibitory effects of a 19 h ibogaine pretreatment, which resemble ibogaine-induced inhibition of morphine's stimulant properties, cannot be accounted for by noribogaine.